Impedimed Limited (AU:IPD) has released an update.
ImpediMed Limited has conveyed optimism about expanding sales and market acceptance in the US and Australia, along with potential product development and commercialization. The company anticipates future revenue growth, profitability, and strong intellectual property positions, while cautioning that these forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties.
For further insights into AU:IPD stock, check out TipRanks’ Stock Analysis page.